Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
RESEARCH TOOLSreports
Holding CAPR?
Track your performance easily
CAPR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.52 - $23.40
Previous Close$14.08
Volume328.82K
Average Volume (3M)2.21M
Market Cap
$621.57M
Enterprise Value$560.21M
Total Cash (Recent Filing)$85.03M
Total Debt (Recent Filing)$5.02M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Mar 06, 2025EPS Estimate
-$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding45,469,908
10 Day Avg. Volume1,389,543
30 Day Avg. Volume2,213,947
Standard Deviation0.73
R-Squared0.08
Alpha0.09
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)9.39
Price to Sales (P/S)27.56
Price to Cash Flow (P/CF)-13.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue24.12
Enterprise Value/Gross Profit22.25
Enterprise Value/Ebitda-16.84
Forecast
1Y Price Target
$41.67Price Target Upside204.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Capricor Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial StrengthRecent equity financing raised $86.3M, boosting Capricor's cash reserves and positioning the company well to achieve key milestone events.
Market PotentialFunctional outcomes data from deramiocel could be the basis of EU approval, where the DMD market is relatively underdeveloped, indicating potential for market expansion.
Regulatory ProgressThe initiation of rolling BLA submission for deramiocel in Duchenne muscular dystrophy represents a significant step towards potential approval.
Bears Say
Drug Development ChallengesPotential hurdles remain for drug development, including the possibility of the FDA requiring additional data, potential manufacturing issues, and the need for an advisory committee meeting.
FDA Approval ProcessA key part of Capricor's thesis is based on extensive discussions with the FDA, and last steps toward approval could see potential hurdles.
Regulatory ApprovalThere is uncertainty as deramiocel may not gain regulatory approval, and Nippon Shinyaku may not meet revenue forecasts.
---
Ownership Overview
16.85% Insiders
5.03% Mutual Funds
8.40% Other Institutional Investors
58.42% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CAPR FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Capricor Therapeutics lowest stock price was $3.52 and its highest was $23.40 in the past 12 months.
What is Capricor Therapeutics’s market cap?
Currently, no data Available
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is Mar 06, 2025 which is in 66 days.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on Nov 13, 2024. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.358 by -$0.022.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -$0.18.
How many shares outstanding does Capricor Therapeutics have?
Capricor Therapeutics has 45,469,910 shares outstanding.
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.358. Following the earnings report the stock price went up 9.344%.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Among the largest hedge funds holding Capricor Therapeutics’s share is Woodline Partners LP. It holds Capricor Therapeutics’s shares valued at N/A.
---
Capricor Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.67 (204.83% Upside)
$41.67 (204.83% Upside)
Blogger Sentiment
Bullish
CAPR Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 12.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
177.16%
12-Months-Change
Fundamentals
Return on Equity
-102.63%
Trailing 12-Months
Asset Growth
150.19%
Trailing 12-Months
Company Description
Capricor Therapeutics
Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.
---
CAPR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Capricor's strategic progress towards FDA approval and market expansion for deramiocel, bolstered by strong financial positioning and positive payer feedback. However, challenges like revenue decline and increased net loss were noted. Despite these challenges, the advancements and positive outlook position the company favorably for future growth.Read More>---
CAPR Stock 12 Month Forecast
Average Price Target
$41.67
▲(204.83% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Eloxx Pharmaceuticals
―
Cellectar Biosciences
―
Brainstorm Cell Therapeutics
―
Best Analysts Covering CAPR
1 Year
1 Year Success Rate
11/13 ratings generated profit
1 Year Average Return
+189.19%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +189.19% per trade.
---